Clinical Aspects and Current Therapeutic Approaches for FOP

• Main Author: Hiroshi Kitoh
• Format: Article
• Language: English
• Published: MDPI AG 2020-09-01
• Series: Biomedicines
• Subjects: fibrodysplasia ossificans progressiva; skeletal malformation; heterotopic ossification; clinical trials
• Online Access: https://www.mdpi.com/2227-9059/8/9/325

Fibrodysplasia ossificans progressiva (FOP) is an extremely rare heritable disorder of connective tissues characterized by progressive heterotopic ossification in various skeletal sites. It is caused by gain-of-function mutations in the gene encoding activin A receptor type I (<i>ACVR1</i>)/activin-like kinase 2 (<i>ALK2</i>), a bone morphogenetic protein (BMP) type I receptor. Heterotopic ossification is usually progressive leading to severe deformities in the trunk and extremities. Early clinical diagnosis is important to prevent unnecessary iatrogenic harm or trauma. Clinicians should become aware of early detectable skeletal malformations, including great toe deformities, shortened thumb, neck stiffness associated with hypertrophy of the posterior elements of the cervical spine, multiple ossification centers in the calcaneus, and osteochondroma-like lesions of the long bones. Although there is presently no definitive medical treatment to prevent, stop or reverse heterotopic ossification in FOP, exciting advances of novel pharmacological drugs focusing on target inhibition of the activated <i>ACVR1</i> receptor, including palovarotene, REGN 2477, rapamycin, and saracatinib, have developed and are currently in clinical trials.